Patents by Inventor John K. Cini

John K. Cini has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ALBUMIN BINDING DOMAIN FUSION PROTEINS
    Publication number: 20220106392
    Abstract: Compositions that include an albumin binding domain and a fusion partner (e.g., a cytokine or a binding moiety) are provided. Such therapeutics have increased serum half-life and find use in applications where one or more such therapeutics are needed, for example, in oncology applications.
    Type: Application
    Filed: May 4, 2021
    Publication date: April 7, 2022
    Inventors: John K. CINI, Haomin HUANG
  • Albumin binding domain fusion proteins
    Patent number: 11028166
    Abstract: Compositions that include an albumin binding domain and a fusion partner (e.g., a cytokine or a binding moiety) are provided. Such therapeutics have increased serum half-life and find use in applications where one or more such therapeutics are needed, for example, in oncology applications.
    Type: Grant
    Filed: February 20, 2018
    Date of Patent: June 8, 2021
    Assignee: SONNET BIO THERAPEUTICS
    Inventors: John K. Cini, Haomin Huang
  • Albumin binding domain fusion proteins
    Publication number: 20190016793
    Abstract: Compositions that include an albumin binding domain and a fusion partner (e.g., a cytokine or a binding moiety) are provided. Such therapeutics have increased serum half-life and find use in applications where one or more such therapeutics are needed, for example, in oncology applications.
    Type: Application
    Filed: February 20, 2018
    Publication date: January 17, 2019
    Inventors: John K. Cini, Haomin Huang
  • ANTIBODIES THAT SPECIFICALLY BIND TO SERUM ALBUMIN WITHOUT INTERFERING WITH ALBUMIN'S CAPABILITY TO INTERACT WITH THE FCRN
    Publication number: 20140186365
    Abstract: Antibodies that specifically bind to an epitope on the serum albumin, including human and/or mouse serum albumin are provided. Nucleic acids encoding such antibodies and cells capable of expressing such antibodies are also provided.
    Type: Application
    Filed: March 14, 2013
    Publication date: July 3, 2014
    Applicants: Institute for Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center, Oncobiologics, Inc.
    Inventors: Matthew K. Robinson, John K. Cini, Jimson W. D'Souza
  • Gel formulations containing growth factors
    Patent number: 5457093
    Abstract: Gel formulations containing polypeptide growth factors having human mitogenic or angiogenic activity are provided. The gel formulations are useful for topical or incisional wound healing for cutaneous wounds, in the anterior chamber of the eye and other ophthalmic wound healing. The gel formulations also comprise a water soluble, pharmaceutically or ophthalmically compatible polymeric material for providing viscosity within various ranges determined by the application of the gel. The gel formulations provide controlled release and increased contact time of the growth factor to the wound site.
    Type: Grant
    Filed: October 12, 1993
    Date of Patent: October 10, 1995
    Assignee: Ethicon, Inc.
    Inventors: John K. Cini, Amy L. Finkenaur
  • Thiol activated protease from stem bromelain for treating devitalized tissue
    Patent number: 5387517
    Abstract: A purified thiol activated protease obtained from bromelain stem extract is provided. The protease has a molecular weight of about 17,000 daltons to about 21,000 daltons and an isoelectric point of about pI 4.5 to about pI 5.0. Methods for obtaining this enzyme and methods for use of this enzyme for debridement of eschar tissue are disclosed.
    Type: Grant
    Filed: March 23, 1994
    Date of Patent: February 7, 1995
    Assignee: Ethicon, Inc.
    Inventor: John K. Cini
  • Stabilized compositions containing epidermal growth factor
    Patent number: 5130298
    Abstract: The present invention provides a pharmaceutical composition comprising a pharmaceutically effective amount of human epidermal growth factor (EGF) and an amount of a pharmaceutically acceptable metal cation, such as zinc, which is sufficient to prevent the degradation of said EGF.
    Type: Grant
    Filed: May 16, 1989
    Date of Patent: July 14, 1992
    Assignee: Ethicon, Inc.
    Inventors: John K. Cini, Amy L. Finkenaur